Shilpa Medicare has received Good Manufacturing Practice (GMP) certification for its Unit 4 facility in Jadcherla, Telangana, from the Austrian Agency for Health and Food Safety (AGES). This approval validates the unit's compliance with European regulatory standards for manufacturing sterile injections and non-sterile oral solid dosage forms.

The certification follows a successful inspection conducted by AGES Austria between July 27, 2026, and July 30, 2026. The intimation was filed with stock exchanges on October 10, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Scope of certified operations

The newly approved facility is designated for the manufacturing, testing, and distribution of specific dosage forms intended for export markets. The scope includes:

• Sterile injections
• Non-sterile tablets
• Non-sterile capsules

These products are targeted at the European market and other global regions. The GMP status is critical for maintaining supply chain continuity and regulatory compliance in these high-value export destinations.

Regulatory context

AGES Austria serves as the competent authority for pharmaceutical inspections in the region. Obtaining this certification ensures that Shilpa Medicare can continue or expand its commercial activities in Europe without regulatory hindrance. The company did not disclose specific revenue implications or capacity expansion details associated with this unit in the filing.

Shilpa Medicare Ltd promoter group members released the encumbrance on 30,00,000 equity shares, representing 1.5337% of the company's paid-up share capital, on September 25, 2026.

The release pertains to pledged shares that were previously encumbered as collateral for self-loans taken by individual promoters from Bajaj Finance Limited. The disclosure was filed with the stock exchanges on September 26, 2026, under Regulation 31 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Breakdown of released shares

The total release of 30,00,000 shares was distributed across six members of the promoter group. Vishnukant C Bhutada saw the largest single release of 10,00,000 shares, while Dharmavati Bhutada, Deepak Kumar Innani, and Ramakant Innani each had 5,00,000 or 6,00,000 shares released. Om Prakash Innani and Brijgopal Innani each had 2,00,000 shares freed from pledge.

Regulatory disclosure details

The filing was submitted to BSE Limited and National Stock Exchange of India Limited. The reason cited for the release in all cases was the repayment or settlement of self-loans for which these shares served as collateral. The entity from which the shares were released is identified as Bajaj Finance Limited in all instances.

What the numbers show

The data indicates a partial reduction in promoter pledging rather than a complete unwinding. For instance, Vishnukant C Bhutada still holds 10,00,000 shares in an encumbered state post-release, which is equal to the number of shares just released. Similarly, Deepak Kumar Innani and Ramakant Innani each retain 8,50,000 encumbered shares after releasing 5,00,000 shares each. This suggests that while liquidity constraints may have eased slightly for specific loan tranches, a significant portion of promoter holdings remains pledged as security.